Clínica EnDi, Mexico City; School of Medicine, Instituto Tecnológico de Monterrey, Mexico City, Mexico.
Centro Nacional para la Prevención y el Control del VIH y el Sida, Mexico City, Mexico.
Rev Invest Clin. 2021 May 4;73(4):222-230. doi: 10.24875/RIC.20000498.
Information regarding diagnosis, treatment, and follow-up of patients with type 1 diabetes (PWT1D) in Mexico is limited. We developed an on-line platform Registro Nacional de Pacientes con Diabetes Tipo 1 (RENACED-DT1).
The objective of the study was to describe the characteristics and healthcare of PWT1D registered in RENACED-DT1.
Analyses of 965 PWT1D from July 2014 to January 2018 in different endocrinology clinics around Mexico.
Sixty-one percent were female with median age of 21 years, age at diagnosis 11 years, and disease duration at inclusion 8.2 years. Treatment regimen was basal-bolus in 61% and insulin-pumps in 21% (mainly in the private sector); 33.3% with self-monitoring of blood-glucose (SMBG) ≥4 times/day. Mean HbA1c at last follow-up was 8.7 ± 2.1% (72±23 mmol/mol), 18% had HbA1c < 7% (53 mmol/mol), and 35% > 9% (75 mmol/mol). SMBG ≥ 4 times/day was associated with HbA1c < 7%. Time since diagnosis > 10 years, female sex, BMI ≥ 30 kg/m2, SMBG < 4 times/day, and any hypoglycemia were associated with microvascular complications (p < 0.05).
Percentage of patients achieving HbA1c < 7% is low; increased blood glucose monitoring is associated with better glycemic control. The achievement of optimal glycemic control must be increased to reduce the incidence of chronic complications and improve quality of life in PWT1D.
有关墨西哥 1 型糖尿病患者(PWT1D)的诊断、治疗和随访信息有限。我们开发了一个在线平台,名为 Registro Nacional de Pacientes con Diabetes Tipo 1 (RENACED-DT1)。
本研究的目的是描述在 RENACED-DT1 中登记的 PWT1D 的特征和医疗保健情况。
对 2014 年 7 月至 2018 年 1 月期间来自墨西哥各地不同内分泌科诊所的 965 名 PWT1D 患者进行分析。
61%为女性,中位年龄为 21 岁,诊断年龄为 11 岁,纳入时病程为 8.2 年。治疗方案为基础-餐时胰岛素方案的占 61%,胰岛素泵的占 21%(主要在私营部门);33.3%的患者进行自我血糖监测(SMBG)≥4 次/天。最近一次随访时的平均 HbA1c 为 8.7±2.1%(72±23mmol/mol),18%的患者 HbA1c<7%(53mmol/mol),35%的患者>9%(75mmol/mol)。SMBG≥4 次/天与 HbA1c<7%相关。诊断后时间>10 年、女性、BMI≥30kg/m2、SMBG<4 次/天和任何低血糖均与微血管并发症相关(p<0.05)。
达到 HbA1c<7%的患者比例较低;增加血糖监测与更好的血糖控制相关。为了降低慢性并发症的发生率并提高 PWT1D 的生活质量,必须提高实现最佳血糖控制的比例。